1. Alaggio R, Amador C, Anagnostopoulos I, et al. (2022): The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36: 1720-1748.
2.
Boyd SD, Natkunam Y, Allen JR, Warnke RA (2013): Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol 21: 116-131.
3.
Novoa V, Núñez NA, Carballo OG, Lessa CF (2013): Inmunofenotipos aberrantes en leucemias agudas en una población hospitalaria de Buenos Aires [Aberrant immunophenotypes in acute leukemia in a Buenos Aires’ hospital population]. Medicina (B Aires) 73: 9-16.
4.
Lu D, Liu YR (2013): Research advances in value of flow cytometric immunophenotyping in diagnosis and prognostic evaluation of myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21: 785-790.
5.
Formenti SC, Turner RR, de Martini RM, et al. (1989): Immunophenotypic analysis of peripheral blood leukocytes at different stages of HIV infection. An analysis of asymptomatic, ARC, and AIDS populations. Am J Clin Pathol 92: 300-307.
6.
Piroozmand A, Hassan ZM (2010): Evaluation of natural killer cell activity in pre and post treated breast cancer patients. J Cancer Res Ther 6: 478-481.
7.
Newman KC, Riley EM (2007): Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nat Rev Immunol 7: 279-291.
8.
Horowitz A, Riley EM (2013): Activation of human NK cells by Plasmodium-infected red blood cells. Methods Mol Biol 923: 447-464.
9.
Mueller AA, Sasaki T, Keegan JW, et al. (2023): High-dimensional immunophenotyping reveals immune cell aberrations in patients with undiagnosed inflammatory and autoimmune diseases. J Clin Invest 133: e169619.
10.
Hoffmann HJ, Santos AF, Mayorga C, et al. (2015): The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy 70: 1393-1405.
11.
Hirosako S, Goto E, Tsumori K, et al. (2010): CD8 and CD103 are highly expressed in asthmatic bronchial intraepithelial lymphocytes. Int Arch Allergy Immunol 153: 157-165.
12.
Xu K, Miao L, Chen W, et al. (2021): Establishment of the reference intervals of lymphocyte subsets for healthy Chinese Han adults and its influencing factors. Ann Transl Med 9: 1495.
13.
Omana-Zapata I, Mutschmann C, Schmitz J, et al. (2019): Accurate and reproducible enumeration of T-, B-, and NK lymphocytes using the BD FACSLyric 10-color system: A multisite clinical evaluation. PLoS One 14: e0211207.
14.
Glier H, Novakova M, Te Marvelde J, et al. (2019): Comments on EuroFlow standard operating procedures for instrument setup and compensation for BD FACS Canto II, Navios and BD FACS Lyric instruments. J Immunol Methods 475: 112680.
15.
Murugesan M, Nair CK, Nayanar SK, Pentapati KC (2019): Flow cytometric enumeration of CD34+ hematopoietic stem cells: A comparison between single- versus dual-platform methodology using the International Society of Hematotherapy and Graft Engineering protocol. Asian J Transfus Sci 13: 43-46.
16.
Avecilla ST, Goss C, Marionneaux SM, et al. (2018): Method comparison study of peripheral blood CD34+ count performed on an Abbott CELL-DYN Sapphire hematology analyzer versus flow cytometry reference procedure (modified ISHAGE). Adv Cell Gene Ther 1: e15.
17.
Kosasih AS, Hayuanta HH, Nasuroh N (2023). Comparison between Sysmex CyFlow Counter and BD FACSCanto II + for counting CD4 Cells in Indonesia. Indonesian J Clin Pathol Med Lab 29: 29-32.
18.
Negedu-Momoh OR, Jegede FE, Yakubu A, et al. (2017): Performance evaluation of BD FACSPresto™ point of care CD4 analyzer to enumerate CD4 counts for monitoring HIV infected individuals in Nigeria. PLoS One 12: e0178037.
19.
Moran Z, Sacks JA, Frimpong FK, et al. (2019): Performance of the BD-FACS Presto for CD4 count and hemoglobin measurement in a district hospital and rural laboratory in Ghana. PLoS One 14: e0212684.
20.
Kingwara L, Stephen KB, Ogada C, et al. (2017): Field evaluation of BD FACSPresto for haemoglobin and CD4 measurement. Clin Med Diagn 7: 57-66.
21.
Lu X, Sun H, Li H, et al. (2020): Validation of the BD FACS- Presto system for the measurement of CD4 T-lymphocytes and hemoglobin concentration in HIV-negative and HIV-positive subjects. Sci Rep 10: 19605.
22.
Makadzange AT, Bogezi C, Boyd K, et al. (2016): Evaluation of the FACSPresto, a new point of care device for the enumeration of CD4% and absolute CD4+ T cell counts in HIV infection. PLoS One 11: e0157546.
23.
Elharti E, Abbadi H, Bensghir R, et al. (2020): Assessment of two POC technologies for CD4 count in Morocco. AIDS Res Ther 17: 31.
24.
Sagnia B, Mbakop Ghomsi F, Gutierrez A, et al. (2020): Performance of the BD FACSPresto near to patient analyzer in comparison with representative conventional CD4 instruments in Cameroon. AIDS Res Ther 17: 53.
25.
Bwana P, Vojnov L, Adhiambo M, et al. (2016): The BD FACSPresto point of care CD4 test accurately enumerates CD4+ T cell counts. PLoS One 10: e0145586.
26.
Malagun M, Nano G, Chevallier C, et al. (2014): Multisite evaluation of point of care CD4 testing in Papua New Guinea. PLoS One 9: e112173.
27.
Grossi V, Infantino M, Meacci F, et al. (2018): Comparison of methods and TAT assessment: Volumetric AQUIOS CL and bead-based FACS CANTO II cytometers. Cytometry. Cytometry B Clin Cytom 94: 674-678.
28.
Verbeek MWC, Rodríguez BS, Sedek L, et al. (2023). Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study. Cytometry B Clin Cytom.
